JP2009538896A5 - - Google Patents

Download PDF

Info

Publication number
JP2009538896A5
JP2009538896A5 JP2009512681A JP2009512681A JP2009538896A5 JP 2009538896 A5 JP2009538896 A5 JP 2009538896A5 JP 2009512681 A JP2009512681 A JP 2009512681A JP 2009512681 A JP2009512681 A JP 2009512681A JP 2009538896 A5 JP2009538896 A5 JP 2009538896A5
Authority
JP
Japan
Prior art keywords
oxo
methyl
dihydropyridazin
fluorobenzoyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009512681A
Other languages
English (en)
Japanese (ja)
Other versions
JP5351755B2 (ja
JP2009538896A (ja
Filing date
Publication date
Priority claimed from GBGB0610680.1A external-priority patent/GB0610680D0/en
Application filed filed Critical
Publication of JP2009538896A publication Critical patent/JP2009538896A/ja
Publication of JP2009538896A5 publication Critical patent/JP2009538896A5/ja
Application granted granted Critical
Publication of JP5351755B2 publication Critical patent/JP5351755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009512681A 2006-05-31 2007-05-25 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）インヒビターとしてのピリジノン及びピリダジノン誘導体 Active JP5351755B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0610680.1A GB0610680D0 (en) 2006-05-31 2006-05-31 Therapeutic compounds
GB0610680.1 2006-05-31
PCT/GB2007/050295 WO2007138351A2 (en) 2006-05-31 2007-05-25 Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp)

Publications (3)

Publication Number Publication Date
JP2009538896A JP2009538896A (ja) 2009-11-12
JP2009538896A5 true JP2009538896A5 (https=) 2013-08-22
JP5351755B2 JP5351755B2 (ja) 2013-11-27

Family

ID=36694627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512681A Active JP5351755B2 (ja) 2006-05-31 2007-05-25 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）インヒビターとしてのピリジノン及びピリダジノン誘導体

Country Status (16)

Country Link
US (1) US8188084B2 (https=)
EP (1) EP2029551B1 (https=)
JP (1) JP5351755B2 (https=)
KR (1) KR101529891B1 (https=)
CN (2) CN101501006A (https=)
AU (1) AU2007266836B2 (https=)
BR (1) BRPI0711741B8 (https=)
CA (1) CA2653529C (https=)
ES (1) ES2702781T3 (https=)
GB (1) GB0610680D0 (https=)
IL (1) IL195113A (https=)
MX (1) MX2008015014A (https=)
NO (1) NO343950B1 (https=)
NZ (1) NZ572815A (https=)
WO (1) WO2007138351A2 (https=)
ZA (1) ZA200809238B (https=)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0622195D0 (en) * 2006-11-08 2006-12-20 Angeletti P Ist Richerche Bio Therapeutic agents
EP2220073B1 (en) * 2007-11-15 2014-09-03 MSD Italia S.r.l. Pyridazinone derivatives as parp inhibitors
DE102008019907A1 (de) * 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
JP5654001B2 (ja) * 2009-04-29 2015-01-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐ２Ｘ７調節因子としての５，６，７，８−テトラヒドロ［１，２，４］トリアゾロ［４，３−ａ］ピラジン誘導体
GB0907515D0 (en) * 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
PL2552920T3 (pl) 2010-04-02 2017-08-31 Ogeda Sa Nowe wybiórcze związki antagonistów receptora NK-3, farmaceutyczne kompozycje i sposoby do zastosowania w zaburzeniach pośredniczonych przez receptory NK-3
US10065960B2 (en) 2010-04-02 2018-09-04 Ogeda Sa NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders
AU2011251622A1 (en) 2010-05-10 2012-12-20 Radikal Therapeutics Inc. Lipoic acid and nitroxide derivatives and uses thereof
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
TWI577693B (zh) 2011-05-31 2017-04-11 江蘇康緣藥業股份有限公司 聚（ａｄｐ-核糖）聚合酶之三環抑制劑
DK2763992T3 (en) 2011-10-03 2016-04-25 Euroscreen Sa NOVEL CHIRAL N-acyl-5,6,7, (8-substituted) -tetrahydro [1,2,4] triazolo [4,3-a] pyrazines as selective NK-3 receptor antagonists, PHARMACEUTICAL COMPOSITION AND METHODS FOR THE use in the NK-3 receptor mediated diseases
CN103570725B (zh) * 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
CN103833756B (zh) * 2012-11-26 2016-12-21 中国科学院上海药物研究所 一类哒嗪酮类化合物及其制备方法和用途
ES2469990B1 (es) * 2012-12-19 2015-01-26 Universidade De Vigo Compuestos de estructura híbrida piridazinona ditiocarbamato con actividad antineoplásica
HUE030613T2 (en) 2012-12-31 2017-05-29 Cadila Healthcare Ltd Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1
PT2975030T (pt) * 2013-03-13 2020-09-28 Chugai Pharmaceutical Co Ltd Derivado de di-hidropiridazina-3,5-diona
ES2753386T3 (es) 2013-03-13 2020-04-08 Forma Therapeutics Inc Derivados de 2-hidroxi-1-{4-[(4-fenil)fenil]carbonil}piperazin-1-il}etano-1-ona y compuestos relacionados como inhibidores de sintasa de ácido graso (FASN) para el tratamiento del cáncer
SG11201508005XA (en) 2013-03-29 2015-10-29 Euroscreen Sa NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
CA2907814C (en) 2013-03-29 2021-07-13 Euroscreen Sa Novel n-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, pharmaceutical composition, methods for use in nk-3 receptor-mediated disorders
US10183948B2 (en) 2013-03-29 2019-01-22 Ogeda Sa N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists
JP6275241B2 (ja) 2013-03-29 2018-02-07 オゲダ エス．エー． 選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−５，６，７，８−テトラヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、その医薬組成物、ＮＫ−３受容体媒介性障害で使用する方法
KR101670126B1 (ko) 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
ES2544869B2 (es) * 2014-03-04 2016-01-18 Universidade De Vigo Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
WO2016054237A2 (en) * 2014-10-03 2016-04-07 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
US10472664B2 (en) 2014-10-03 2019-11-12 Institute For Cancer Research Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors
EP3265560B1 (en) 2015-03-02 2021-12-08 Sinai Health System Homologous recombination factors
AU2016296905B2 (en) 2015-07-23 2018-07-05 Centre National De La Recherche Scientifique Use of a combination of Dbait molecule and parp inhibitors to treat cancer
CN106749261A (zh) * 2015-11-23 2017-05-31 中国科学院上海药物研究所 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
LT3483164T (lt) 2017-03-20 2020-05-11 Forma Therapeutics, Inc. Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai
CN109232575B (zh) * 2017-07-10 2022-01-25 中国科学院上海药物研究所 吡咯[1,2-b]哒嗪类化合物或其可药用盐及它们的用途
CA3092779A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
FI3788040T3 (fi) 2018-04-30 2023-06-13 Ribon Therapeutics Inc Pyridatsinoneja parp7-inhibiittoreina
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
EP3853206B1 (en) 2018-09-19 2024-04-10 Novo Nordisk Health Care AG Treating sickle cell disease with a pyruvate kinase r activating compound
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
WO2020223229A1 (en) 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
HRP20251148T1 (hr) 2019-09-19 2025-11-21 Novo Nordisk Health Care Ag Pripravci koji aktiviraju piruvat-kinazu r (pkr)
WO2021087025A1 (en) 2019-10-30 2021-05-06 Ribon Therapeutics, Inc. Pyridazinones as parp7 inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
AU2020444056A1 (en) 2020-04-21 2022-11-17 Idience Co., Ltd. Crystalline forms of phthalazinone compound
JP7626783B2 (ja) 2020-04-21 2025-02-07 アイディーエンス カンパニー リミテッド フタラジノン誘導体及びその中間体を調製するプロセス
US12059419B2 (en) 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2022223022A1 (zh) * 2021-04-23 2022-10-27 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
JP2024528021A (ja) * 2021-07-29 2024-07-26 上海齊魯制藥研究中心有限公司 新規なｐａｒｐ７阻害剤及びその使用
CN117897380A (zh) * 2021-08-17 2024-04-16 益方生物科技(上海)股份有限公司 哒嗪酮或吡啶酮化合物、其制备方法和用途
AU2022375782B2 (en) * 2021-10-28 2026-02-26 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN115745971B (zh) * 2021-12-20 2024-07-30 北京华森英诺生物科技有限公司 Parp7抑制剂及其应用
JP7763538B2 (ja) * 2022-04-01 2025-11-04 諾沃斯達薬業（上海）有限公司 Ｐａｒｐ７阻害剤及びその使用
JP2025534359A (ja) * 2022-09-30 2025-10-15 アズカラ セラピューティクス インク ピリダジン－３（２ｈ）－オンおよびピリジン－２（１ｈ）－オンのＰＡＲＰ阻害化合物
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
CN121398822A (zh) 2023-06-21 2026-01-23 四方生物科学有限公司 用于在治疗hr功能正常的癌症的方法中的用途的包含脱氧胞苷衍生物和parp抑制剂的组合
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
CA2205757C (en) * 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
WO2002090334A1 (en) 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
EP1411941A2 (en) * 2001-08-02 2004-04-28 Neurocrine Biosciences, Inc. Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists
US7211779B2 (en) 2001-08-14 2007-05-01 Transchip, Inc. Pixel sensor with charge evacuation element and systems and methods for using such
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
CN100469769C (zh) * 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
JP4627315B2 (ja) * 2004-03-23 2011-02-09 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体
PE20060285A1 (es) 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
WO2005100323A1 (en) * 2004-04-15 2005-10-27 F. Hoffmann-La Roche Ag Process for preparing pyridazinone compounds
JP2008510783A (ja) 2004-08-26 2008-04-10 クドス ファーマシューティカルズ リミテッド ４−ヘテロアリールメチル置換フタラジノン誘導体
DK1919878T3 (da) * 2005-07-21 2010-10-25 Hoffmann La Roche Pyridazinonderivater som thyroidhormonreceptoragonister
CA2623728A1 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Nnrt inhibitors
CA2647545C (en) * 2006-04-03 2016-02-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
WO2007138355A1 (en) * 2006-05-31 2007-12-06 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-a]pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase(parp)
US8466150B2 (en) * 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
ES2548353T3 (es) * 2006-12-28 2015-10-15 Abbvie Inc. Inhibidores de poli(ADP-ribosa)polimerasa
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
WO2011055270A1 (en) * 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists

Similar Documents

Publication Publication Date Title
JP2009538896A5 (https=)
RU2405771C2 (ru) Гетероциклические замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1
RU2503676C2 (ru) Пирролопиразиновые ингибиторы киназы
AU2019240299B2 (en) SHP2 phosphatase inhibitors and methods of use thereof
JP2014506929A5 (https=)
ES2778700T3 (es) Nuevos derivados de piperidinilo sustituidos con (hetero)arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
RU2005117383A (ru) Производные фенилаланина в качестве ингибиторов дипептидилпептидазы для лечения или профилактики диабета
RU2443706C2 (ru) Фармацевтические соединения
JP2011500774A5 (https=)
BR112021001292A2 (pt) compostos heterobicíclicos para inibir a atividade de shp2
JP2011516512A5 (ja) 新規な置換スピロ[シクロアルキル−１,３'−インドール]−２'(１'Ｈ)−オン誘導体およびｐ３８マイトジェン活性化タンパク質キナーゼ阻害剤としてのそれらの使用
HRP20120105T1 (hr) Aminoheterociklički spojevi
AU2024332123A1 (en) Compositions comprising werner syndrome helicase inhibitors and methods of using the same
RU2012152548A (ru) Пиридоновые и азапиридоновые соединения и способы применения
JP2018522046A5 (https=)
JP2012510998A5 (https=)
JP2010524984A5 (https=)
JP2022502424A5 (https=)
RU2014123316A (ru) Ингибиторы фосфодиэстеразы типа 10а
ME02330B (me) Derivati 2,3-dihidro-1h-inden-1-il-2,7-diazaspir0[3.6]nonana i njihova upotreba kao antagonista ili inverznih agonista grelinskog receptora
AU2009218459A1 (en) Imidazo [1,2-B] pyridazine derivatives for the treatment of C-Met tyrosine kinase mediated disease
RU2015129538A (ru) Замещенные имидазопиридины в качестве ингибиторов hdm2
AU2011253057A1 (en) Nitrogen heterocyclic compounds useful as PDE10 inhibitors
JP2013522238A5 (https=)
JP2015522002A5 (https=)